There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC …

In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus
(HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently …

Background & Aims Recently, the PAGE-B score and Toronto HCC risk index (THRI) have
been developed to predict the risk of hepatocellular carcinoma (HCC) in Caucasian patients …

The Chinese Society of Hepatology, Chinese Medical Association (CMA) and the Society of
Infectious Diseases, CMA organized relevant native experts to establish this Guideline of …

The last 50 years of hepatitis B research has resulted in the development of effective
screening assays for surveillance, vaccines for prevention and antiviral drugs that …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Background & Aims Treatment for hepatitis B virus infection reduces the risk of
hepatocellular carcinoma (HCC). However, the long-term protective effects for subgroups of …

Abstract Background & Aims Oral antiviral therapy may reduce the disease progression of
chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long‐term …

BACKGROUND Efficacy trials have shown that antiviral therapy improves the outcomes of
patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding …